Emma Walmsley Sells 38,459 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 38,459 shares of the stock in a transaction that occurred on Monday, February 17th. The shares were sold at an average price of GBX 1,418 ($17.92), for a total transaction of £545,348.62 ($689,006.47).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The stock was sold at an average price of GBX 1,453 ($18.36), for a total transaction of £1,753,088.09 ($2,214,893.35).

GSK Stock Down 1.2 %

Shares of LON:GSK opened at GBX 1,429 ($18.05) on Friday. The firm has a fifty day moving average price of GBX 1,377.06 and a two-hundred day moving average price of GBX 1,450.11. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. GSK plc has a one year low of GBX 1,282.50 ($16.20) and a one year high of GBX 1,823.50 ($23.04). The company has a market cap of £57.99 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GSK has been the subject of several analyst reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank cut their price objective on shares of GSK from GBX 1,820 ($22.99) to GBX 1,600 ($20.21) and set a “buy” rating for the company in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of GBX 1,805.83 ($22.82).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.